Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients

Journal of Neuroimmunology

Volumn 98, Issue 2, 1999, Pages 221-226

  Saito, Mineki ^a   Nakamura, Norio ^b   Nagai, Masahiro ^a,c   Shirakawa, Kamon ^b   Sato, Hironori ^b   Kawahigashi, Nobuko ^a   Furukawa, Yoshitaka ^a   Usuku, Koichiro ^a   Nakagawa, Masanori ^a   Izumo, Shuji ^c   Osame, Mitsuhiro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

^c Kagoshima University   (Japan)

Author keywords

Anti HTLV 1 antibody; CSF; HAM TSP; Soluble human Fas ligand

Indexed keywords

ANTIBODY; FAS LIGAND; MESSENGER RNA; NEOPTERIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; INFLAMMATION; MALE; PRIORITY JOURNAL; SERUM; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FAS LIGAND PROTEIN; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPTERIN; PARAPARESIS, TROPICAL SPASTIC; RNA, MESSENGER; SOLUBILITY; VIRAL LOAD;

EID: 0033052896     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00095-8     Document Type: Article

References (39)

1. Ali A., Rudge P., Dalgleish A.G. Neopterin concentrations in serum and cerebrospinal fluid in HTLV-1 infected individuals. J. Neurol. 239:1992;270-272.
2. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
3. Daenke S., Kermode A.G., Hall S.E., Taylor G., Weber J., Nightingale S., Bangham C.R.M. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology. 217:1996;139-146.
4. Elovaara I., Koenig S., Brewah A.Y., Woods R.M., Lehky T., Jacobson S. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J. Exp. Med. 117:1993;1567-1573.
5. Gessain A., Barin F., Vernant J.C., Gout O., Maurs L., Calende A., De The G. Antibodies to human T-lymphotropic virus type-1 in patients with tropical spastic paraparesis. Lancet. 2:1985;407-410.
6. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
7. Hashimoto H., Tanaka M., Suda T., Tomita T., Hayashida K., Takeuchi E., Kaneko M., Takano H., Nagata S., Ochi T. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 41:1998;657-662.
8. Inoue A., Koh C.S., Sakai T., Yamazaki M., Yanagisawa N., Usuku K., Osame M. Detection of soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. J. Neuroimmunol. 75:1997;141-146.
9. Jacobson S., Gupta A., Mattson D., Mingioli E., McFarlin D.E. Immunological studies in tropical spastic paraparesis. Ann. Neurol. 27:1990;149-156.
10. Jacobson S., Shida H., McFarlin D.E., Fauci A.S., Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-1 pX in patients with HTLV-1 associated neurological disease. Nature. 348:1990;245-248.
11. Kanda Y., Tanaka Y., Shirakawa K., Yatomi T., Nakamura N., Kami M., Saito T., Izutsu K., Asai T., Yuji K., Ogawa S., Honda H., Mitani K., Chiba S., Yazaki Y., Hirai H. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplantation. 22:1998;751-754.
12. Kannagi M., Harada S., Maruyama I., Inoko H., Igarashi H., Kuwashima G., Sato S., Morita M., Kidokoro M., Sugimoto M., Funahashi S., Osame M., Shida H. Predominant recognition of human T-cell leukemia virus type 1 (HTLV-1) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-1-infected cells. Int. Immunol. 8:1991;761-767.
13. Kannagi M., Shida H., Igarashi H., Kuruma K., Murai H., Aono Y., Maruyama I., Osame M., Hattori T., Inoko H., Harada S. Target epitope in the Tax protein of human T-cell leukemia virus type-1 recognized by class I major histocompatibility complex-restricted cytotoxic T cells. J. Virol. 66:1992;2928-2933.
14. Kaplan J.E., Osame M., Kubota H., Igata A., Nishitani H., Maeda Y., Khabbaz R.F., Janssen R.S. The risk of development of HTLV-1 associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-1. J. Acquired Immune Defic. Syndr. 3:1990;1096-1101.
15. Kawahigashi N., Furukawa Y., Saito M., Usuku K., Osame M. Predominant expression of Fas ligand mRNA in CD8+ T lymphocytes in patients with HTLV-1 associated myelopathy. J. Neuroimmunol. 90:1998;199-206.
16. + T lymphocytes. Ann. Neurol. 40:1996;84-90.
17. Nagai M., Usuku K., Matsumoto W., Kodama D., Takenouchi N., Moritoyo T., Hashiguchi S., Ichinose M., Bangham C.R.M., Izumo S., Osame M. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. J. NeuroVirol. 4:1998;586-593.
18. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
19. Nakagawa M., Izumo S., Ijichi S., Kubota H., Arimura K., Kawabata M., Osame M. HTLV-1 associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J. NeuroVirol. 1:1995;50-61.
20. Nishimoto N., Yoshizaki K., Eiraku N., Machigashira K., Tagoh H., Ogata A., Kuritani T., Osame M., Kishimoto T. Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Neurol. Sci. 97:1990;183-193.
21. Nomoto M., Utatsu Y., Soejima Y., Osame M. Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-1 associated myelopathy/tropical spastic paraparesis. Neurology. 41:1991;457.
22. Osame, M., 1991. HAM/TSP: Global review and WHO Diagnostic guidelines. In: Chopra, J.S. (Ed.), Advances in Neurology. Elsevier, Amsterdam, pp. 265-271.
23. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1:1986;1031.
24. Osame M., Matsumoto M., Usuku K., Izumo S., Ijichi N., Amitani H., Tara M., Igata A. Chronic progressive myelopathy associated with elevated antibodies to HTLV-1 and adult T-cell leukemia cells. Ann. Neurol. 21:1987;117-122.
25. Parker C.E., Daenke S.D., Nightingale S., Bangham C.R.M. Activated HTLV-1 specific cytotoxic T cells are found in healthy seropositives as well as patients with tropical spastic paraparesis. Virology. 188:1992;628-636.
26. Parker C.E., Nightingale S., Taylor G.P., Weber J., Bangham C.R.M. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type-1-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J. Virol. 68:1994;2860-2868.
27. Poiesz B.J., Ruscetti R.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T cell lymphoma. Proc. Natl. Acad. Sci. USA. 77:1980;7415-7419.
28. Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:1995;3806-3813.
29. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:1997;2045-2050.
30. Tanaka M., Suda T., Takahashi T., Nagata S. Expression of functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1995;1129-1135.
31. Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S., Hatake K., Drummond A.H., Nagata S. Fas ligand in human serum. Nat. Med. 2:1996;317-322.
32. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 4:1998;31-36.
33. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T cell leukemia: clinical and hematologic features of 16 cases. Blood. 50:1977;481-491.
34. Umehara F., Izumo S., Nakagawa M., Ronquillo A.T., Takahashi K., Matsumuro K., Sato E., Osame M. Immunocytochemical analysis of the infiltrate in the spinal cord lesions in HTLV-1-associated myelopathy. J. Neuropathol. Exp. Neurol. 52:1993;424-430.
35. Umehara F., Nakamura A., Izumo S., Kubota R., Ijichi S., Kashio N., Hashimoto K., Usuku K., Sato E., Osame M. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-1-associated myelopathy: a possible mechanism to control viral infection in the central nervous system. J. Neuropathol. Exp. Neurol. 53:1994;617-624.
36. Umehara F., Okada Y., Fujimoto N., Abe M., Izumo S., Osame M. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in HTLV-1 associated myelopathy. J. Neuropathol. Exp. Neurol. 57:1998;839-849.
37. Walakovits L.A., Moore V.L., Bhardwaj N., Gallick G.S., Lark M.W. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum. 35:1992;35-42.
38. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA. 79:1982;2031-2035.
39. Yoshida M., Seiki M., Yamaguchi K., Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in disease. Proc. Natl. Acad. Sci. USA. 81:1984;2534-2537.